Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
22 April 2024 - 10:00PM
Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”)
(Nasdaq: CPRX), a commercial-stage biopharmaceutical company
focused on in-licensing, developing, and commercializing novel
medicines for patients living with rare and difficult-to-treat
diseases, today announced that it will release its first quarter
2024 financial results after the market close on Wednesday,
May 8, 2024. Catalyst's management team will host a conference call
and webcast on Thursday, May 9, 2024, at 8:30 AM ET to discuss
the Company's financial results and provide a business update.
Conference Call & Webcast Details |
Date: |
May 9,
2024 |
Time: |
8:30 AM ET |
US/Canada Dial-in Number: |
(877) 407-8912 |
International Dial-in Number: |
(201) 689-8059 |
|
|
The webcast will be accessible under the
Investors section on the Company's website at
www.catalystpharma.com. A webcast replay will be available on the
Catalyst website for 30 days following the date of the event.
About Catalyst Pharmaceuticals, Inc.
With exceptional patient focus, Catalyst is
committed to developing and commercializing innovative
first-in-class medicines that address rare and difficult-to-treat
diseases. Catalyst's flagship U.S. commercial product is
FIRDAPSE® (amifampridine) Tablets 10 mg, approved for the treatment
of Lambert-Eaton myasthenic syndrome ("LEMS") for adults
and for children ages six to seventeen. In January 2023,
Catalyst acquired the U.S. commercial rights to FYCOMPA®
(perampanel) CIII, a prescription medicine approved in people with
epilepsy aged four and older alone or with other medicines to treat
partial-onset seizures with or without secondarily generalized
seizures and with other medicines to treat primary generalized
tonic-clonic seizures for people with epilepsy aged 12 and older.
Further, Canada's national healthcare regulatory
agency, Health Canada, has approved the use of FIRDAPSE for
the treatment of adult patients in Canada with LEMS.
On July 18, 2023, Catalyst acquired an exclusive license
for North America for AGAMREE® (vamorolone) oral
suspension 40 mg/mL, a novel corticosteroid treatment for Duchenne
Muscular Dystrophy. AGAMREE previously received FDA Orphan Drug and
Fast Track designations and was approved by the FDA for
commercialization in the U.S. on October 26, 2023.
AGAMREE became commercially available by prescription in the U.S.
on March 13, 2024.
For more information about Catalyst
Pharmaceuticals, Inc., please visit the Company's website
at www.catalystpharma.com. For Full Prescribing and Safety
Information for FIRDAPSE®, please visit www.firdapse.com. For
Full Prescribing Information, including Boxed WARNING for FYCOMPA®,
please visit www.fycompa.com. For Full Prescribing Information
for AGAMREE®, please visit www.agamree.com.
Forward-Looking Statements
This press release contains forward-looking
statements, as that term is defined in the Private Securities
Litigation Reform Act of 1995. Forward-looking statements involve
known and unknown risks and uncertainties, which may cause
Catalyst's actual results in future periods to differ materially
from forecasted results. A number of factors, including those
factors described in Catalyst's Annual Report on Form 10-K for the
fiscal year 2023 and its other filings with the U.S.
Securities and Exchange Commission ("SEC"), could adversely
affect Catalyst. Copies of Catalyst's filings with
the SEC are available from the SEC, may be found on
Catalyst's website, or may be obtained upon request from Catalyst.
Catalyst does not undertake any obligation to update the
information contained herein, which speaks only as of this
date.
Source: Catalyst Pharmaceuticals, Inc.
Investor Contact
Mary Coleman, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
mcoleman@catalystpharma.com
Media Contact
David Schull, Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Apr 2024 to May 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From May 2023 to May 2024